Last updated on November 2018

Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia

Brief description of study



Primary Objectives: To evaluate the clinical efficacy of the sequential combination of hyper-CVAD + blinatumomab in patients with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) in terms of relapse-free survival (RFS)

Secondary Objectives: To evaluate other efficacy endpoints such as overall survival, overall response rate, MRD negativity rate as well as the safety of this combination.

Clinical Study Identifier: NCT02877303

Contact Investigators or Research Sites near you

Start Over

Elias Jabbour, MD

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.